High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Federica Sora', Patrizia Chiusolo, Simona Sica, Luca Laurenti, Barbara Vannata, Idanna Innocenti, Francesco Autore, Giuseppe Leone

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody with a high efficacy in fludarabine- and alemtuzumab-refractory B cell chronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage with the addiction of high dose corticosteroids to the Ofa at standard dose in this type of patients, obtaining an OR rate of 78%, have recently been published in the literature [3].
Original languageEnglish
Pages (from-to)E133-E133
JournalAmerican Journal of Hematology
Volume87
DOIs
Publication statusPublished - 2012

Keywords

  • Chronic Lymphocytic Leukemia

Fingerprint

Dive into the research topics of 'High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this